Breast cancer
Conditions
Interventions
Experimental group:Calcium dobesilate capsules
Control group:None
Sponsors
The Fourth Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Aged >= 18 years; 2.Patients with breast cancer confirmed by histopathology; 3.Patients plan to receive at least 4 cycles of pegylated liposomal doxorubicin treatment; 4.ECOG Performance Status is 0-2; 5.Life expectancy >=3 months; 6.Patients voluntarily join the study, sign informed consent, have good compliance and are willing to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating; 2.Patients with a past history of hand-foot syndrome and no recovery to grade 2 or below at screening; 3.Serious diseases (including but not limited to nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolic and endocrine system, etc.); 4.The researcher believes that the patient is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence and severity of hand-foot syndrome caused by pegylated liposomal doxorubicin from the beginning of chemotherapy to the end of the fourth cycle; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time of first occurrence of hand-foot syndrome caused by pegylated liposomal doxorubicin;Proportion of all degrees of hand-foot syndrome during the follow-up period;Proportion of patients with delayed or reduced dose of pegylated liposomal doxorubicin due to hand-foot syndrome during treatment;Quality of life assessment; | — |
Countries
China
Contacts
Public ContactSong Zhenchuan
The Fourth Hospital of Hebei Medical University
Outcome results
None listed